GleamWall
中文EN

NERV Minerva Neurosciences, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1598646 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-1,973.5%
TTM EPS YoY-1,728.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-460.3%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets187.3%
Debt / equity—
Current ratio33.02x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.11x
Accruals ratio-410.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$5.16M$7.19M$5.25M$2.17M$925,377$1.30M$1.36M$1.98M
SG&A expense$4.28M$3.45M$11.42M$2.81M$1.92M$2.08M$2.54M$2.54M
Operating income-$9.43M-$10.64M-$16.67M-$4.98M-$2.84M-$3.37M-$3.90M-$4.52M
Net income$100.75M$17.47M-$125.40M-$283.67M-$2.74M-$3.26M-$3.75M-$4.27M
EBITDA———-$4.98M-$2.84M-$3.37M-$3.90M-$4.52M
EPS (basic)1.940.36-2.86—-0.36-0.43-0.50—
EPS (diluted)-0.19-0.14-2.86—-0.36-0.43-0.50—
Weighted avg. shares (diluted)75.25M79.10M43.90M—7.57M7.57M7.57M—
Balance sheet
Cash & equivalents$20.22M$24.65M$32.66M$82.30M$12.29M$15.25M$17.29M$21.36M
Short-term investments$56.73M$50.62M$45.41M—————
Current assets$83.41M$79.73M$79.11M$83.10M$13.02M$15.55M$17.92M$22.27M
PP&E, net———$0$1,360$2,721$4,081$5,442
Goodwill$14.87M$14.87M$14.87M$14.87M$14.87M$14.87M$14.87M$14.87M
Total assets$98.28M$95.09M$94.03M$97.97M$28.09M$30.42M$32.80M$37.14M
Current liabilities$2.53M$3.96M$4.48M$2.29M$2.67M$2.53M$1.95M$2.84M
Total liabilities$184.06M$296.65M$343.08M$233.76M$62.67M$62.53M$61.95M$62.84M
Shareholders' equity-$97.52M-$213.30M-$254.01M-$140.75M-$34.58M-$32.11M-$29.15M-$25.69M
Shares outstanding49.84M47.23M43.84M43.27M6.99M6.99M6.99M6.99M
Cash flow statement
Operating cash flow-$8.15M-$13.34M-$5.43M-$4.48M-$2.92M-$2.04M-$4.07M-$5.17M
Investing cash flow-$5.73M-$4.83M-$45.29M$0$0$0$0$0
Financing cash flow$9.44M$10.17M$1.08M$74.50M-$45,166$0$0—
Depreciation & amortization———$1,360$1,361$1,360$1,361$1,360
Stock-based compensation$3.21M$2.27M$8.71M$459,028$272,897$298,218$297,229$249,650

Free plan shows the latest 8 periods; Pro shows all 55 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.